Trial
NCT02405442
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Gilead Sciences
Collaborators
—
Condition
Crohn's Disease
Intervention
Andecaliximab
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-04-23